Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.73 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8544209 | 0.99 | APEX1 (0.75) | APEX1MCOLN3TSHRHSD17B10POLB | |
| SCHEMBL8541971 | 0.96 | APEX1 (0.75) | APEX1MCOLN3TSHRHSD17B10POLB | |
| Ethyl Acetate SCHEMBL9031428 | 0.90 | KMT2A (0.65) | APEX1MCOLN3POLBALDH1A1KMT2A | |
| SCHEMBL1645604 | 0.88 | APEX1 (0.72) | APEX1TSHRHSD17B10POLBTP53 | |
| SCHEMBL8540145 | 0.87 | APEX1 (0.70) | APEX1MCOLN3TSHRHSD17B10POLB | |
| SCHEMBL8540322 | 0.87 | POLB (0.73) | APEX1POLBALDH1A1KMT2A | |
| SCHEMBL25705600 | 0.83 | APEX1 (0.65) | APEX1MCOLN3HSD17B10POLBTP53 | |
| SCHEMBL7205052 | 0.83 | GPBAR1 (0.88) | MCOLN3TSHRHSD17B10ALDH1A1GPBAR1 | |
| SCHEMBL11167770 | 0.83 | TSHR (0.54) | APEX1MCOLN3TSHRHSD17B10POLB | |
| SCHEMBL8545158 | 0.82 | APEX1 (0.64) | APEX1MCOLN3HSD17B10POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| EP-2280001-B1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD KK (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8420823-B2 | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD K.K. (JP) | 2013-04-16 | — | — | US | disclosed |
| EP-2280001-A1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-02-02 | — | — | EP | disclosed |
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD K.K. (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| EP-1615904-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092135-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA (SE) | 2004-10-28 | — | — | WO | disclosed |
| EP-0705259-B1 | PHENYRROLE DERIVATIVES AND THEIR USE AS DOPAMINE D3 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | ELOVL1, ELOVL6, ELOVL3 | APEX1 2400/4885MCOLN3 3299/4885TSHR 3094/4885 |
| US-20070021606-A1 | Therapeutic compounds | GRIN1, GRIN3A, GRM2 | APEX1 2053/4885MCOLN3 2415/4885TSHR 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.